Content
08/15/2024
Ann Arbor, MI USA
HistoSonics
completed $102 million Series D Round funding. Investors include
Alpha Wave Global (lead), Amzak Health, HealthQuest Capital, Johnson & Johnson Innovation, Lumira Ventures, State of Wisconsin Investment Board, Yonjin Venture.
About
HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.
Startup
Sector:
MedTech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
